Bruce House in Ottawa, Ontario, Canada, has been serving individuals living with HIV and AIDS for 34-plus years. Here we speak with Patrick Morley, office and communications coordinator.
U=U, or Undetectable=Untransmittable, is a science-backed consensus statement detailing how individuals living with HIV/AIDS who get to an undetectable viral load and are able to maintain that by adhering to their antiretroviral treatment can’t sexually transmit the virus to their partners. In Canada, this level is below 40 or 50 copies/mL.
Patrick Morley, office and communications coordinator for Bruce House in Ottawa, Ontario, Canada, which has been serving individuals living with HIV and AIDS for 34-plus years, speaks about how the organization continues to express the importance of U=U.
Transcript
How do you live the message of U=U and educate others about it?
I was very proud when Bruce House signed the U=U consensus statement. I’m even more proud that so many agencies have now and the Public Health Agency of Canada recognizes the statement as valid. But I’ll have to admit that when we first signed it, as a nonprofit sector, you advocate and then you get what you advocated for and there’s that “Now what?” moment. I was a little bit unsure how we were going to proceed, because we don’t have an education mandate, so “Okay, I have to put this message out in context.”
And also very early on, I became aware of what’s been called the third view, which is “unequal.” Not everyone living with HIV can achieve an undetectable viral load. Some people just get a low viral load, but it’s detectable. And, what is required to be on HIV treatment? Well, you have to take a pill every day. That was my lightbulb moment, because that’s our reason to exist at Bruce House: What is keeping you from being in treatment? Is it because you don’t have a home, you don’t have food, you have other concerns?
So as we’ve moved forward, we’ve seen how U=U is so fundamental to what we do. So if we talk about HIV stigma, let’s say we’re speaking to a group of health care providers or social service providers, there is no doubt, here is a statement endorsed by leading health authorities, backed by research. You are not at risk from your clients and patients.
It’s a comprehensive evidence-based argument, so when we talk about things like treatment as prevention, here is proof that somebody under treatment can likely not transmit HIV as long as they get an undetectable viral load. It’s a good argument to support things that may be controversial, like PrEP [preexposure prophylaxis]. Again, you’re not only preventing transmission, but you are also preventing that person from further transmitting if they are infected.
And it’s so affirming for people living with HIV, that connection. One of the first stories about U=U I heard was at a group presentation, somebody in the audience left crying. So one of the facilitators do what you’re supposed to do [and] go to the hallway and say, “Are you okay?” And the person apparently was crying out of joy and relief. For years they had lived with fear and guilt, feeling that every time they had sex with their partner, they could transmit HIV. And they just communicated that it was that sense of relief. That sense of, “I no longer have to worry, ‘Did the condom break? Did we do something we shouldn’t have?'” It was that sense of relief, it was affirming.
To wrap up, for us, U=U is one of the foundations we build our work on, in the same way we build out work on culturally appropriate services, on indigenous reconciliation, on understanding people’s challenges, on nonjudging. This is a cornerstone of our work now, and I’m very proud of that.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More